Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-10T08:26:49.871Z Has data issue: false hasContentIssue false

Intracellular cytokine expression in invasive fungal sinusitis and its impact on patient outcome

Published online by Cambridge University Press:  02 March 2022

P Verma
Affiliation:
Department of ENT, All India Institute of Medical Sciences, New Delhi, India
K Sikka*
Affiliation:
Department of ENT, All India Institute of Medical Sciences, New Delhi, India
H Verma
Affiliation:
Department of ENT, All India Institute of Medical Sciences, New Delhi, India
A Thakar
Affiliation:
Department of ENT, All India Institute of Medical Sciences, New Delhi, India
D K Mitra
Affiliation:
Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India
A Saurabh
Affiliation:
Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India
G Singh
Affiliation:
Division of Mycology, Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
*
Author for correspondence: Dr Kapil Sikka, Room 4063, ENT Office, Academic Block, All India Institute of Medical Sciences, New Delhi110029, India E-mail: kapil_sikka@yahoo.com

Abstract

Background

Cell-mediated immunity plays an important role in host defence against fungal pathogens, regulated by differentiation of lymphocytes towards T-helper 1 or 2 cells. This study reports intracellular cytokine variation in terms of invasive fungal sinusitis type and outcome.

Methods

The mononuclear leukocytes of 15 patients with invasive fungal sinusitis (mucormycosis in 8, aspergillus in 7) were stained with antibodies against intracellular cytokines, after fungal antigen stimulation and culture, and immunophenotyped. Patients were followed up for six months, with clinical course categorised as improvement, worsening or death.

Results

The mean percentages of mononuclear cells producing interleukins 4, 5, 10 and 12, and interferon-γ, in the mucormycosis group were 0.575, 0.284, 8.661, 4.460 and 1.134, respectively, while percentages in the aspergillosis group were 0.233, 0.492, 4.196, 4.466 and 1.533. Cells producing interleukin 4 and 10 were higher in the mucormycosis group, while those producing interleukin-12 and interferon-γ were lower. Cells producing interleukins 4 and 12 were higher in patients with a poor outcome (p-values of 0.0662 and 0.0373, respectively), while those producing interferon-γ were lower (p = 0.0864).

Conclusion

Adaptive cell-mediated immunity is expressed differently in two categories of invasive fungal sinusitis, and the cytokine expression pattern is related to prognosis.

Type
Main Article
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dr K Sikka takes responsibility for the integrity of the content of the paper

References

O'Brien, HE, Parrent, JL, Jackson, JA, Moncalvo, JM, Vilgalys, R. Fungal community analysis by large scale sequencing of environmental samples. Appl Environ Microbiol 2005;71:5544–50CrossRefGoogle ScholarPubMed
Köhler, JR, Casadevall, A, Perfect, J. The spectrum of fungi that infects humans. Cold Spring Harb Perspect Med 2014;5:a019273CrossRefGoogle ScholarPubMed
Casadevall, A. Fungal virulence, vertebrate endothermy, and dinosaur extinction: is there a connection? Fungal Genet Biol 2005;42:98106CrossRefGoogle ScholarPubMed
Casadevall, A. Fungi and the rise of mammals. PLoS Pathog 2012;8:e1002808CrossRefGoogle ScholarPubMed
Chakrabarti, A, Chatterjee, SS, Shivaprakash, MR Overview of opportunistic fungal infections in India. J Med Mycol 2008;49:165–72CrossRefGoogle ScholarPubMed
Antachopoulos, C. Invasive fungal infections in congenital immunodeficiencies. Clin Microbiol Infect 2010;16:1335–42CrossRefGoogle ScholarPubMed
Ghuman, H, Voelz, K. Innate and adaptive immunity to Mucorales. J Fungi (Basel) 2017;3:48CrossRefGoogle ScholarPubMed
Dambuza, IM, Levitz, SM, Netea, MG, Brown, GD. Fungal recognition and host defense mechanisms. Microbiol Spectr 2017;5(4)CrossRefGoogle ScholarPubMed
Davis, MJ, Tsang, TM, Qiu, Y, Dayrit, JK, Freij, JB, Huffnagle, GB et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio 2013;4:e00264–13CrossRefGoogle ScholarPubMed
Potenza, L, Vallerini, D, Barozzi, P, Riva, G, Forghieri, F, Zanetti, E et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood 2011;118:5416–19CrossRefGoogle ScholarPubMed
Lafferty, KJ, Warren, HS, Woolnough, JA, Talmage, DW. Immunological induction of T lymphocytes: role of antigen and the lymphocyte costimulator. Blood Cells 1978;4:395406Google ScholarPubMed
Tramsen, L, Schmidt, S, Boenig, H, Latgé, JP, Lass-Flörl, C, Roeger, F et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting candida, aspergillus and mucormycetes. Cytotherapy 2013;15:344–51CrossRefGoogle ScholarPubMed
Singh, V. Fungal rhinosinusitis: unravelling the disease spectrum. J Maxillofac Oral Surg 2019;18:164–79CrossRefGoogle ScholarPubMed
Beaman, L. Fungicidal activation of murine macrophages by recombinant gamma interferon. Infect Immun 1987;55:2951–5CrossRefGoogle ScholarPubMed
Brummer, E, Stevens, DA. Antifungal mechanisms of activated murine bronchoalveolar or peritoneal macrophages for Histoplasma capsulatum. Clin Exp Immunol 1995;102:6570CrossRefGoogle ScholarPubMed
Novak, ML, Koh, TJ. Macrophage phenotypes during tissue repair. J Leukoc Biol 2013;93:875–81CrossRefGoogle ScholarPubMed
Abzug, MJ, Walsh, TJ. Interferon-γ and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004;23:769–73CrossRefGoogle ScholarPubMed
Castellano-Gonzalez, G, Clancy, LE, Gottlieb, D. Prospects for adoptive T-cell therapy for invasive fungal disease. Curr Opin Infect Dis 2017;30:518–27CrossRefGoogle ScholarPubMed
Grimaldi, D, Pradier, O, Hotchkiss, RS, Vincent, JL. Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis 2017;17:18CrossRefGoogle ScholarPubMed
Ito, JI. T cell immunity and vaccines against invasive fungal diseases. Immunol Invest 2011;40:825–38CrossRefGoogle ScholarPubMed